



November 13, 2024

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: News Release - Unaudited Financial Results for the quarter and half year ended on September 30, 2024.

We send herewith a copy of the News Release that is being issued by the Company today, in connection with the captioned subject.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,
for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No. ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com



Bayer CropScience Limited
Communications
Bayer House, Hiranandani Estate
Thane (West) - 400607
Maharashtra, India
www.bayer.in

News Release

Quarterly Results

Bayer CropScience Limited reports Q2 Results for FY 2024-25

- Revenue from Operations of ₹17,376 million
- Profit Before Tax of ₹1,901 million

Mumbai, November 13, 2024: Bayer CropScience Limited (BSE: 506285) announced today its unaudited results for the quarter (Q2) and half year ended (H1) September 30, 2024.

For Q2 ended September 30, 2024, Bayer CropScience Limited (BCSL) registered Revenue from Operations of ₹17,376 million as compared to ₹16,172 million in the corresponding period of FY 2023-24. Profit Before Tax stood at ₹1,901 million, compared to ₹3,057 million in the corresponding period of the previous financial year.

For the H1 ended September 30, 2024, BCSL reported Revenue from Operations of ₹33,688 million compared to ₹33,568 million for the corresponding period in FY 2023-24. Profit Before Tax for the H1 ended September 30, 2024, stood at ₹5,059 million, compared to ₹7,118 million for the corresponding period in FY 2023-24.

Commenting on the quarterly results, Simon Wiebusch, Vice Chairman & Managing Director and CEO, BCSL said, "In Q2 BCSL achieved a 7% increase in Revenue from Operations primarily driven by higher volumes which were partially offset by price pressure rooted in lower producer prices in China. Moreover, our margins were negatively impacted by higher production costs in corn seeds due to adverse weather conditions as well as a higher cost of goods sold in our chemical business. Despite these headwinds, we are looking forward to a stronger rabi and spring season, delivering sustainable, long-term value for our stakeholders."

Speaking about the quarterly results, Simon Britsch, Chief Financial Officer, BCSL said, "We maintain our strong focus on cash flow generation and prudent operational expense management. However, we witnessed one-time effects from higher receivables and employee severance provisions. As we look forward, we are confident in our ability to continue with further growth investments and distributing a significant share of our profit to our owners."

The Board of Directors at its meeting held on November 13, 2024, declared an interim dividend of ₹ 90/- per equity share for the financial year ending March 31, 2025, amounting to ₹ 4,045 Million.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive

impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Media Contact

Snigdha Vishal

Communications, Bayer CropScience Limited

E-mail: snigdha.vishal@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.